Aspen Neuroscience Nabs FDA RMAT Designation for its Parkinson’s Cell Therapy
The designation gives Aspen added FDA support as it advances sasineprocel, a personalized autologous cell therapy for Parkinson’s disease, through clinical development.
Key Points
- Aspen Neuroscience said the FDA granted RMAT designation to sasineprocel (ANPD001) for Parkinson’s disease.
- Sasineprocel is Aspen’s lead investigational autologous (sourced from the patient) cell therapy and is being studied in the Phase 1/2a ASPIRO trial.
- The designation adds to a broader 2025 to 2026 update cycle that includes clinical dosing progress, 12-month trial data, manufacturing expansion, and formal adoption of the nonproprietary name sasineprocel.
Aspen Neuroscience received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001) as a treatment for Parkinson’s disease. Sasineprocel is the company’s lead investigational therapy; it’s a dopaminergic neuronal precursor cell (DANPC) therapy for moderate-to-advanced Parkinson’s disease (PD), derived from autologous induced pluripotent stem cells (iPSCs). The therapy is currently in a Phase 1/2a at UCSF.
RMAT designation is given to companies with promising regenerative therapies for serious conditions with unmet needs, and can support interactions with the FDA during development.
Clinical and development updates
In March 2026, the company presented 12-month data from the ASPIRO study at the AD/PDTM 2026 conference and said the results showed continued safety, tolerability, and sustained clinical benefit. Those are company-reported findings from an ongoing early-stage trial.
Outside the clinic, Aspen said the World Health Organization and the American Medical Association’s United States Adopted Names Council cleared sasineprocel as the official nonproprietary name for ANPD001. The company also announced leadership additions in 2025 and 2026, including appointments in legal, medical, commercial, and finance roles.
Aspen’s recent updates also include manufacturing automation efforts, a collaboration and license agreement with Cell X Technologies, multiple scientific conference presentations, and a $115 million Series C financing announced in November 2025.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
